证券代码：301559 证券简称：中集环科 公告编号：2024-048 中集安瑞环科技股份有限公司 关于公司 2025 年度为子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 担保情况概述 为满足中集安瑞环科技股份有限公司（以下简称"公司"）控股子公司中集 绿建环保新材料（连云港）有限公司（以下简称"中集绿建连云港"）及中集环 境服务有限公司（以下简称"中集环服"）日常经营和业务发展需要，确保资金 流畅，公司在保证规范运营和风险可控的前提下，拟为其提供连带责任保证担 保。 2025年度，公司拟为中集绿建连云港向银行或其他金融机构申请的综合授 信额度提供不超过人民币2,000万元的连带责任保证担保； 2025年度，公司拟为中集环服向银行或其他金融机构申请的综合授信额度 提供不超过人民币2,000万元的连带责任保证担保。 上述担保额度期限自股东会审议通过之日起12个月内，上述担保额度在有 效期限内可以循环使用，担保期限内任一时点的担保余额不超过股东会审议通 过的担保额度。对超出上述担保对象及总担保额度范围之外的担保，公司将根 据规 ...

中集安瑞环科技股份有限公司 关于公司 2025 年度向银行申请综合授信额度的公告 证券代码：301559 证券简称：中集环科 公告编号：2024-049 2024 年 12 月 13 日 公司董事会授权公司总裁或总裁指定的授权人根据实际经营情况的需要，在 综合授信额度内办理授信与贷款等具体事宜，并签署上述授信额度内的一切授信 及用信有关的合同、协议、凭证等各项法律文件，由此产生的法律、经济责任全 部由公司承担。 本次申请综合授信额度事项无需提交股东会审议。 二、备查文件 第二届董事会第七次会议决议。 特此公告。 中集安瑞环科技股份有限公司 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 中集安瑞环科技股份有限公司（以下简称"公司"）于 2024 年 12 月 13 日召 开第二届董事会第七次会议审议通过了《关于公司 2025 年度向银行申请综合授 信额度的议案》，具体情况如下： 一、本次申请银行授信额度的基本情况 为满足公司的经营发展需要，保障公司稳健运营，2025 年度公司拟向银行 申请不超过人民币 24 亿元的综合授信额度。授权期限为自董事会审议通 ...

证券代码：301559 证券简称：中集环科 公告编号：2024-051 中集安瑞环科技股份有限公司 关于续聘 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 中集安瑞环科技股份有限公司（以下简称"公司"）于 2024 年 12 月 13 日 召开了第二届董事会第七次会议及第二届监事会第七次会议，审议通过了《关于 续聘 2024 年度审计机构的议案》，同意续聘中汇会计师事务所（特殊普通合伙） （以下简称"中汇会所"）为公司 2024 年度审计机构，该议案尚需提交公司 2024 年第三次临时股东会审议。现将具体情况说明如下： 一、拟续聘 2024 年度审计机构的情况说明 中汇会所具有从事证券、期货相关业务资格，具备多年为上市公司提供审计 服务的执业经验与能力，具有良好的职业操守和较强的风险意识，能够独立、客 观、公正地开展审计工作，具备足够的投资者保护能力。中汇会所在独立性、专 业胜 ...

中信证券股份有限公司 关于中集安瑞环科技股份有限公司 继续开展外汇套期保值业务的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为中集安瑞环 科技股份有限公司（以下简称"中集环科"或"公司"）首次公开发行股票并在深圳 证券交易所创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》和《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关规定，对中集环科开展远期结售汇和外汇期权业务事项进行了审慎核查，具体 情况如下： 为防止汇率出现较大波动时，汇兑损益对公司的经营业绩及利润造成不利影 响，公司拟同金融机构进行额度不超过 5 亿美元的远期结售汇业务，进行额度不 超过 2.5 亿美元的外汇期权业务，具体方案如下： 一、开展远期结售汇和外汇期权业务的目的 公司日常经营中的进出口业务主要采用美元、欧元等外币进行结算，为防止 汇率出现较大波动时，汇兑损益对公司的经营业绩及利润造成不利影响，公司拟 开展远期结售汇和外汇期权业务。 公司开展远期结售汇和外汇期权是以正常生产经营为前提，使用自有资金开 展远期结售汇和外汇期权业务有利于规避人民币汇率变动风险，有利于提高公司 抵御 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [5][6] Core Views - The company has shown resilience in its business operations, with a quarter-on-quarter revenue improvement of 25.19% in Q3, despite a year-on-year decline of 24.23% [1] - The company has signed new orders totaling 2.208 billion RMB for the period from January to September 2024, with a backlog of 1.11 billion RMB as of September 30 [1] - The medical equipment segment has seen a revenue increase of 4.18% year-on-year, indicating a positive trend in this area [2] Financial Performance Summary - Q3 revenue was 964 million RMB, down 24.23% year-on-year but up 25.19% quarter-on-quarter [1] - For the first three quarters of 2023, total revenue was 2.354 billion RMB, a decrease of 38.63% year-on-year [1] - The company forecasts net profit attributable to shareholders for 2024-2026 to be 302 million, 445 million, and 543 million RMB respectively, with year-on-year growth rates of -49%, 48%, and 22% [1][9] Market Outlook - The overseas chemical market is expected to recover, with signs of a cyclical upturn as demand for chemical products increases [3] - The report highlights that the company, as an industry leader, is likely to benefit significantly from the recovery in order volumes and the resilience of its tank manufacturing business [3] Valuation Metrics - The target price for the company is set at 18.65 RMB, with a projected price-to-book ratio of 2.5x for 2025 [1][5] - The report anticipates that the company's return on equity (ROE) will remain significantly above the industry average, reflecting its strong market position [1]

Group 1: Company Overview - The company is the largest global manufacturer of tank containers, with a comprehensive range of products and leading technology [2] - It integrates design, research and development, manufacturing, and sales of chemical logistics equipment [2] Group 2: Financial Performance - In Q3 2024, the company achieved operating revenue of 964.42 million CNY, a 25.19% increase compared to Q2 2024 [2] - Revenue breakdown: tank container revenue was 810.23 million CNY (up 29.06%), medical device components revenue was 68.68 million CNY (up 19.16%), while aftermarket business revenue was 34.41 million CNY (down 8.45%) [2] Group 3: Shareholder Confidence - Shareholders voluntarily extended the lock-up period for shares by 24 months until October 2026, reflecting confidence in the company's future and commitment to small shareholders [3] - This decision supports the company's strategic goals and aims to enhance investor confidence [3] Group 4: Market Opportunities - The company is positioned to benefit from the recent "M&A Six Guidelines" issued by the CSRC, which encourages mergers and acquisitions in the industry [3] - The company is expanding its applications in new fields such as semiconductors, new energy, and biomedicine, leveraging its industry influence [3] Group 5: Order and Production Management - From January to September 2024, the company signed new orders totaling 2.208 billion CNY, with a backlog of 1.11 billion CNY as of September 30, 2024 [3] - Production and delivery will be arranged based on order status [3] Group 6: Currency Impact - In Q3 2024, the company faced significant fluctuations in the RMB/USD exchange rate, impacting profits as products are primarily settled in USD [3] - The company manages exchange rate risks through financial instruments like forward contracts [3] Group 7: Dividend Policy - The company has a three-year dividend plan (2024-2026) stating that cash dividends should not be less than 50% of the distributable profits for the year [4] - Cumulative cash dividends since listing amount to 771 million CNY, with a current dividend yield of 7.67% as of October 22 [4]

财联社10月22日讯（记者 武超） 中集环科（301559.SZ）此前曾披露过，从第二季度开始，下游客户提 箱速度加快，客户询单开始活跃，公司订单数量持续增加。从今日晚间发布的财报来看，中集环科第三 季度相比今年前两季度，营收、净利润下滑幅度有所收窄，但改善并不明显。 根据中集环科财报，前三季度，公司营业收入为23.54亿元，同比下降38.63%；归属净利润为1.80亿 元，同比下降62.98%，整体呈现营收、净利双降的态势。 另据Wind数据，前三季度，公司毛利率为16.78%，较同期下降5.16个百分点；净利率为7.55%，较同期 下降5.06个百分点。 分季度来看，中集环科Q3实现营业总收入9.64亿元，同比下降24.23%，环比增长25.19%；归属净利润 6503.66万元，同比下降49.32%，环比增长3.14%。 公开资料显示，中集环科是全球规模最大、技术领先的罐式集装箱制造龙头和全生命周期服务商。今年 上半年，公司罐式集装箱全球市场份额蝉联第一。罐箱行业是典型的周期成长型行业，需求端主要挂钩 全球化工品物流需求，但此前行业经历多季度承压，呈现出弱复苏的态势，导致罐式集装箱市场需求有 所放缓。 ...

Financial Performance - Revenue for Q3 2024 was CNY 964,416,198.78, a decrease of 24.23% year-over-year, and a decline of 38.63% for the year-to-date period[2] - Net profit attributable to shareholders for Q3 2024 was CNY 65,036,596.96, down 49.32% year-over-year, with a year-to-date decline of 62.98%[2] - Basic earnings per share for Q3 2024 was CNY 0.11, a decrease of 56.00% compared to the same period last year[2] - The company reported a decrease of 8.45% in after-market business revenue in Q3 2024 compared to Q2 2024[10] - The net profit for Q3 2024 was CNY 177,825,699.50, a decrease of 63.2% compared to CNY 483,568,613.16 in the same period last year[16] - The total profit for Q3 2024 was CNY 206,442,377.66, down 63.5% from CNY 566,618,992.81 year-on-year[16] - The basic and diluted earnings per share for Q3 2024 were both CNY 0.3, compared to CNY 0.95 in Q3 2023, reflecting a decline of 68.4%[17] - The operating profit for Q3 2024 was CNY 205,063,551.98, down 63.5% from CNY 561,519,896.41 in Q3 2023[16] - The company reported a total comprehensive income of CNY 179,044,563.81 for Q3 2024, a decrease of 63.0% from CNY 484,676,320.30 in the previous year[17] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 5,420,215,803.69, a decrease of 2.90% from the end of the previous year[2] - Cash and cash equivalents at the end of the period are CNY 2,073,695,114.52, down from CNY 2,876,944,465.70, representing a decrease of about 28.0%[12] - Total assets decreased to CNY 5,420,215,803.69 from CNY 5,581,938,346.00, a reduction of approximately 2.9%[14] - Total liabilities decreased to CNY 838,559,627.22 from CNY 919,022,185.07, reflecting a decline of about 8.8%[14] - The company's equity attributable to shareholders decreased to CNY 4,583,838,513.69 from CNY 4,662,844,409.26, a decrease of approximately 1.7%[14] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 266,175,140.58, down 51.65% year-over-year[6] - Cash inflow from operating activities for Q3 2024 was CNY 2,460,101,646.70, down 41.5% from CNY 4,198,667,910.46 in the previous year[18] - Cash outflow from investing activities totaled CNY 1,367,093,960.26 in Q3 2024, significantly higher than CNY 130,141,633.96 in Q3 2023[19] - The net cash flow from investing activities was negative CNY 739,519,360.27, compared to negative CNY 129,291,633.96 in the same quarter last year[19] - The cash and cash equivalents at the end of Q3 2024 were CNY 2,072,244,267.76, down from CNY 3,704,308,295.88 at the end of Q3 2023[19] Revenue Segments - The company achieved operating revenue of CNY 2,354.15 million for the first nine months of 2024, representing a 61.37% increase compared to the same period last year[10] - In Q3 2024, the company reported operating revenue of CNY 964.42 million, a 25.19% increase from Q2 2024, with container revenue growing by 29.06%[10] - The medical equipment components segment generated CNY 171.29 million in revenue, exceeding last year's performance by 104.18%[10] Investment and Funding - The company plans to use CNY 600 million of temporarily idle raised funds for cash management, investing in high-security, liquid products with a maturity of no more than 12 months[11] - The board approved the use of CNY 300 million of excess raised funds to permanently supplement working capital for daily operations[11] - The company has adjusted the internal investment structure and construction period for certain fundraising projects while maintaining the original investment purposes[10] Other Financial Metrics - The company experienced a 175.25% increase in credit impairment losses, mainly due to changes in accounts receivable[5] - Investment income increased by 63.11% year-over-year, attributed to gains from foreign exchange contracts and equity transfers[5] - Non-operating income decreased by 78.43% year-over-year, primarily due to fewer compensation receipts compared to the previous year[5] - Research and development expenses decreased to CNY 89,713,934.69 from CNY 123,356,141.37, a decline of approximately 27.2%[15] - The company reported a net investment loss of CNY 19,042,225.97, an improvement compared to a loss of CNY 51,621,781.76 in the previous period[15] - The company’s financial expenses showed a significant improvement, with a net financial income of CNY 30,731,057.96 compared to a loss in the previous period[15] - The company’s inventory decreased to CNY 922,746,772.93 from CNY 970,715,930.82, a decline of approximately 4.9%[12]

近日，公司开立了募集资金现金管理产品专用结算账户，账户具体信息如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 中集安瑞环科技股份有限公司（以下简称"公司"）于 2024 年 8 月 19 日召 开第二届董事会第五次会议、第二届监事会第五次会议，于 2024 年 9 月 6 日召 开 2024 年第二次临时股东大会，审议通过了《关于使用暂时闲置募集资金进行 现金管理的议案》，同意在确保不影响正常生产经营和募集资金投资计划的情况 下，公司及子公司使用不超过人民币 60,000 万元的暂时闲置募集资金（含超募 资金）进行现金管理，用于购买安全性高、流动性好的投资产品，该额度自公司 股东大会审议通过后 12 个月内可循环滚动使用。具体内容详见公司于 2024 年 8 月 21 日刊登在巨潮资讯网的《关于使用暂时闲置募集资金进行现金管理的公 告》。 一、开立募集资金现金管理产品专用结算账户的情况 证券代码：301559 证券简称：中集环科 公告编号：2024-042 中集安瑞环科技股份有限公司 关于开立募集资金现金管理产品专用结算账户并签署募集 资金三方监管协议 ...

证券代码：301559 证券简称：中集环科 公告编号：2024-041 中集安瑞环科技股份有限公司 关于相关股东自愿延长股份锁定期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、珠海鹏瑞森茂持有公司股份的情况 1 | 首发前限售股 | 24,843,899 | 4.14% | 限售期限为 10 | 2023 | 年 | 月 | 11 | | --- | --- | --- | --- | --- | --- | --- | --- | | 股份类别 | 股数（股） | 占总股本比例 | 限售情况的说明 日至 2024 10 | 年 | 月 | 10 | 日 | 注：珠海鹏瑞森茂最近十二个月内未发生减持公司股票的情况。 二、有关股份锁定期承诺情况 公司首次公开发行股票并在创业板上市前，公司股东珠海鹏瑞森茂就发行上 市前所持股份的锁定期承诺如下： 1、自本企业取得中集环科股份之日起 36 个月内或自中集环科本次发行上市 之日起 12 个月内（二者按孰晚之日为准），本企业不转让或者委托他人管理本 企业在本次发行上市前直接或间接持有的中集环科股份，也不由中 ...